1. [No authors listed.] FDA approves new drug to treat multiple sclerosis. US Food and Drug Administration
https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm
(2017).
2. [No authors listed.] New medicine for multiple sclerosis. European Medicines Agency
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/11/news_detail_002847.jsp&mid=WC0b01ac058004d5c1
(2017).
3. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).
4. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Multiple Sclerosis (European Medicines Agency, 2015).
5. U.S. Food and Drug Administration. Ocrelizumab Summary Review. US Food and Drug Administration
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000SumR.pdf
(2017).